Geneus Technologies was established in 2017 and is a high-tech company dedicated to the development and commercialization of fourth-generation (nanopore) gene sequencers and reagents. Its technology core is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and high-throughput sequencing of nucleic acids at the single molecule level through a highly integrated chip system. With the Nobel Prize participants and the world's top nanopore sequencing experts as the core, Geneus Technologies has established a R & D team including senior experts in China and the United States in biochemistry, integrated circuits, materials, MEMS, organic synthesis, algorithms, etc., which has basically covered the professional fields required for the development of fourth-generation gene sequencers. The goal of Geneus Technologies is not only to break the monopoly of foreign countries in the field of sequencing equipment and reagents based on self-developed intellectual property rights, but also to use revolutionary technological breakthroughs to completely surpass the current popular second-generation sequencing technology in core indicators such as the quality (read length, sensitivity, coverage, etc.) and cost of sequencing data, subvert the existing sequencing field pattern, and achieve the goal of "a few hours, a few hundred yuan" to perform whole gene sequencing, and fully advance human whole genome sequencing into the clinical application field, so as to promote the development of precision medicine industry in both diagnosis and treatment, and thus become the leader in the global market related to up to 600 billion US dollars.nucleic acids at the single-molecule level through a highly integrated system on a chip. With Nobel Prize participants and the world's top nanopore sequencing experts as the core, we have set up a research and development team including senior experts in biochemistry, integrated circuits, materials, MEMS, organic synthesis, algorithms and other directions, which has basically covered the professional fields needed for the development of the fourth-generation gene sequencer.